Guggenheim Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $52

Benzinga · 6d ago
Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $57 to $52.